Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 7Rectal Neoplasms 2Inflammatory Breast Neoplasms 2Colonic Neoplasms 2Malignant Solid Neoplasm 1

Interventions

Leucovorin 38Fluorouracil 36Oxaliplatin 34Bevacizumab 34Irinotecan 32Cetuximab 23Capecitabine 18Panitumumab 14IFL protocol 7Folfox protocol 6Celecoxib 6Radiotherapy 5Nivolumab 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gene Expression Profiling 5regorafenib 4pembrolizumab 4dehydroftorafur 4Ramucirumab 4Fluorodeoxyglucose F18 4Floxuridine 4aflibercept 3Surgical Procedures, Operative 3Sorafenib 3Radiosurgery 3Ipilimumab 3Gemcitabine 3Fentanyl 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Colonic Neoplasms × 2C4 antibody × Clear all
NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

SWOG Cancer Research Network

Phase 2 Completed
240 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00551421 2015-03-31

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡